Amyloidosis
Pathology · Topic 9
Source: NMC CBME Curriculum 2024 · Volume I · Pathology · Topic 9 · combined PDF page 190
Practice questions
- Which sequence best describes the pathogenesis of AL amyloidosis?
- A tissue biopsy contains amyloid, and the patient has a circulating monoclonal light chain. Which conclusion is most appropriate?
- Which histochemical finding is classically used to demonstrate amyloid in tissue?
- Why is identifying the amyloidogenic protein important after amyloid is detected in a tissue sample?
- Which combination of tests is specifically identified as enhancing clinical suspicion of AL amyloidosis?
- A clinician suspects systemic AL amyloidosis. Which statement best characterizes the role of serum and urine immunofixation and serum free light-chain testing?
- In the ASH guideline abstract, what combination constitutes the described surrogate-biopsy approach for diagnosing AL amyloidosis?
- A patient with suspected AL amyloidosis has a clinical situation in which surrogate sampling may not be the preferred route to confirmation. Which biopsy strategy is recognized as an alternative in selected cases?
- Which set of organs is explicitly recognized as potentially involved in AL amyloidosis?
- Why can systemic amyloidosis produce a high symptom burden?
- According to the British Society for Haematology guideline abstract, what is a major determinant of survival in systemic AL amyloidosis?
- Which statement best captures the clinical presentation of AL amyloidosis?
- A pathologist receives a tissue sample with suspected systemic amyloidosis. Which laboratory priority is emphasized in the pathology guideline?
- Which statement most accurately distinguishes amyloid detection from amyloid typing?
- A patient has cardiac amyloidosis and peripheral neuropathy. Which amyloid subtype is especially associated with concurrent cardiac and neurologic phenotypes in the review?
- In ATTR-related amyloidosis, which statement about neurologic involvement is supported by the review?
- A clinician is assessing disease burden in systemic amyloidosis. Which statement about cardiac and neurologic involvement is most accurate?
- In the meta-analysis of screening studies, which clinical setting had the highest pooled prevalence of cardiac amyloidosis in the whole enrolled cohort?
- Which comparison of whole-cohort pooled cardiac amyloidosis prevalence is correct according to the screening meta-analysis?
- In screening studies, why can the estimated prevalence of cardiac amyloidosis be higher among participants who undergo confirmatory testing than in the whole enrolled cohort?
- Which approach did the screening meta-analysis recommend to obtain more reliable population prevalence estimates?
- Which statement about non-cardiac bone scintigraphy cohorts is consistent with the screening meta-analysis?
- Across clinical screening settings in the meta-analysis, which cardiac amyloidosis subtype predominated?
- A patient with suspected cardiac amyloidosis is seen in a general medical clinic rather than a specialist hematology clinic. Which principle is supported by the AL recognition guideline?
- Why does early recognition of AL amyloidosis matter, according to the supplied guidelines?
- A laboratory is reviewing its approach to suspected systemic amyloidosis. Which statement best reflects the pathology guideline's concern?
- A patient has suspected AL amyloidosis with possible involvement of several organs. Which diagnostic principle best fits the supplied guideline recommendations?
- A patient with amyloidosis has cardiac and neurologic manifestations. Which interpretation best reflects the review's description of the relationship between these domains?